---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-102065"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:21:39.158441+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# RxSight appoints former Axonics CEO Raymond Cohen to board of directors

## Summary
- Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.
- Cohen also led SoniVie sale to Boston Scientific for $600M; has over 40 years medtech experience.
- Will serve until 2028 annual meeting; receives standard non-employee director compensation including $277,500 initial RSU grant.
- Press release issued August 4, 2025; no other changes to board or management.

## SEC filing metadata
- accession: 0000950170-25-102065
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017025102065/0000950170-25-102065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017025102065/rxst-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-102065
- JSON: https://secwatch.observer/filing/0000950170-25-102065.json
- Plain text: https://secwatch.observer/filing/0000950170-25-102065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.